- Home
- SPRO vs NB Comparison
SPRO vs NB Comparison
Compare SPRO & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- NB
- Stock Information
- Founded
- SPRO 2013
- NB 1987
- Country
- SPRO United States
- NB United States
- Employees
- SPRO N/A
- NB N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- NB Metal Mining
- Sector
- SPRO Health Care
- NB Basic Materials
- Exchange
- SPRO Nasdaq
- NB Nasdaq
- Market Cap
- SPRO 62.7M
- NB 56.9M
- IPO Year
- SPRO 2017
- NB N/A
- Fundamental
- Price
- SPRO $1.17
- NB $1.39
- Analyst Decision
- SPRO Buy
- NB Strong Buy
- Analyst Count
- SPRO 3
- NB 1
- Target Price
- SPRO $5.00
- NB $8.50
- AVG Volume (30 Days)
- SPRO 470.6K
- NB 251.6K
- Earning Date
- SPRO 11-14-2024
- NB 11-13-2024
- Dividend Yield
- SPRO N/A
- NB N/A
- EPS Growth
- SPRO N/A
- NB N/A
- EPS
- SPRO 0.06
- NB N/A
- Revenue
- SPRO $106,455,000.00
- NB N/A
- Revenue This Year
- SPRO N/A
- NB N/A
- Revenue Next Year
- SPRO N/A
- NB N/A
- P/E Ratio
- SPRO $17.92
- NB N/A
- Revenue Growth
- SPRO 37.01
- NB N/A
- 52 Week Low
- SPRO $1.01
- NB $1.27
- 52 Week High
- SPRO $1.89
- NB $4.00
- Technical
- Relative Strength Index (RSI)
- SPRO 41.49
- NB 36.89
- Support Level
- SPRO $1.28
- NB $1.33
- Resistance Level
- SPRO $1.22
- NB $1.46
- Average True Range (ATR)
- SPRO 0.07
- NB 0.09
- MACD
- SPRO -0.01
- NB -0.01
- Stochastic Oscillator
- SPRO 32.73
- NB 27.27
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.